drugset / Trial / NCT00399906

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

NCT00399906

Phase 2 Completed 99 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of each dose will also be studied.

Timeline

Start
2007-08
Primary completion
2009-01
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator BMS-582949 Small molecule 10 mg Oral
Comparator BMS-582949 Small molecule 30 mg Oral
Comparator BMS-582949 Small molecule 100 mg Oral

Indications